{"hands_on_practices": [{"introduction": "The cornerstone of pharmacological analysis is quantifying the relationship between ligand concentration and biological effect. This exercise guides you through deriving the Hill equation from the first principles of mass-action kinetics for a dimeric nuclear receptor, a common scenario in signaling. By fitting this model to a hypothetical dataset [@problem_id:4590975], you will practice the essential skill of extracting key parameters like potency ($EC_{50}$) and cooperativity ($n$) from experimental data, linking biophysical theory to practical data analysis.", "problem": "A pharmacologist is quantifying the transcriptional activity of a ligand-activated Nuclear Receptor (NR) using a luciferase reporter in a human cell line. The NR is known to bind DNA as a homodimer and requires ligand binding for transcriptional activation. Assume the following foundations: (i) equilibrium binding governed by the law of mass action, (ii) the measured reporter output is proportional to the fraction of active receptor complexes, and (iii) cooperative ligand binding arises from the dimeric activation mechanism. Using these principles only, derive a minimal concentration–response function that relates the effect $E$ to the free ligand concentration $[L]$ and the parameters $E_{\\max}$ (maximum effect), $EC_{50}$ (half-maximal effective concentration), and the Hill coefficient $n$ (apparent cooperativity).\n\nThen, using the dose–response data below (means of background-subtracted replicates), fit $E_{\\max}$, $EC_{50}$, and $n$ from the data by an analysis consistent with the model you derived. The ligand concentration $[L]$ is given in $\\mathrm{nM}$ and the reporter output $E$ is in arbitrary luminescence units (a.u.):\n\n- $[L] = 0.3 \\ \\mathrm{nM}$, $E = 0.0107903 \\ \\text{a.u.}$\n- $[L] = 1 \\ \\mathrm{nM}$, $E = 0.118812 \\ \\text{a.u.}$\n- $[L] = 3 \\ \\mathrm{nM}$, $E = 0.990826 \\ \\text{a.u.}$\n- $[L] = 10 \\ \\mathrm{nM}$, $E = 6.00000 \\ \\text{a.u.}$\n- $[L] = 30 \\ \\mathrm{nM}$, $E = 10.8000 \\ \\text{a.u.}$\n- $[L] = 100 \\ \\mathrm{nM}$, $E = 11.8812 \\ \\text{a.u.}$\n- $[L] = 300 \\ \\mathrm{nM}$, $E = 11.9878 \\ \\text{a.u.}$\n- $[L] = 10000 \\ \\mathrm{nM}$, $E = 12.0000 \\ \\text{a.u.}$\n\nReport only your final estimate of $EC_{50}$, expressed in $\\mathrm{nM}$ and rounded to three significant figures. Do not include any other quantities in your final answer.", "solution": "The problem requires a two-part response: first, the derivation of a minimal concentration-response function based on the provided biophysical principles, and second, the fitting of this model to the supplied experimental data to determine the parameter $EC_{50}$.\n\n**Part 1: Derivation of the Concentration-Response Function**\n\nThe problem states that the nuclear receptor (NR) acts as a ligand-activated transcription factor that binds to DNA as a homodimer. This activation process is governed by equilibrium binding and the law of mass action. The simplest, or minimal, model consistent with these facts, particularly the requirement for a homodimer and the origin of cooperativity from this dimeric mechanism, involves the concerted binding of two ligand molecules to a receptor dimer to form the transcriptionally active complex.\n\nLet $D$ represent the inactive receptor homodimer and $L$ represent the ligand. The formation of the active complex, denoted as $DL_2$, can be represented by the following equilibrium reaction:\n$$\nD + 2L \\rightleftharpoons DL_2\n$$\nAccording to the law of mass action, the association constant, $K_a$, for this reaction is given by:\n$$\nK_a = \\frac{[DL_2]}{[D][L]^2}\n$$\nwhere $[D]$, $[L]$, and $[DL_2]$ are the equilibrium concentrations of the inactive dimer, free ligand, and active complex, respectively.\n\nThe problem states that the measured reporter output, or effect $E$, is proportional to the fraction of active receptor complexes. Let us define this fraction, $\\theta$, as the concentration of active complexes divided by the total concentration of receptor dimers, $[D]_{\\text{total}}$.\n$$\n[D]_{\\text{total}} = [D] + [DL_2]\n$$\nThus, the fraction of active complexes is:\n$$\n\\theta = \\frac{[DL_2]}{[D]_{\\text{total}}} = \\frac{[DL_2]}{[D] + [DL_2]}\n$$\nFrom the equilibrium expression, we can write $[DL_2] = K_a [D] [L]^2$. Substituting this into the expression for $\\theta$:\n$$\n\\theta = \\frac{K_a [D] [L]^2}{[D] + K_a [D] [L]^2}\n$$\nThe common term $[D]$ cancels from the numerator and denominator, yielding:\n$$\n\\theta = \\frac{K_a [L]^2}{1 + K_a [L]^2}\n$$\nIt is more conventional to work with a dissociation constant, $K_D$, which is the inverse of the association constant, $K_D = 1/K_a$. Substituting $K_a = 1/K_D$ into the expression for $\\theta$:\n$$\n\\theta = \\frac{([L]^2/K_D)}{1 + ([L]^2/K_D)} = \\frac{[L]^2}{K_D + [L]^2}\n$$\nThe relationship between the observable effect $E$ and the fractional activity $\\theta$ is one of proportionality. The maximum effect, $E_{\\max}$, is achieved when all receptors are in the active state, i.e., when $\\theta = 1$. Therefore, the proportionality constant is $E_{\\max}$, giving the relationship $E = E_{\\max} \\cdot \\theta$.\nSubstituting the expression for $\\theta$, we obtain the concentration-response function:\n$$\nE([L]) = E_{\\max} \\frac{[L]^2}{K_D + [L]^2}\n$$\nThis equation is a specific instance of the Hill equation, which is generally written as:\n$$\nE([L]) = E_{\\max} \\frac{[L]^n}{EC_{50}^n + [L]^n}\n$$\nBy comparing our derived function with the general Hill equation, we identify the Hill coefficient (an index of cooperativity) as $n=2$. This integer value is a direct consequence of the minimal model for dimeric activation. Furthermore, by comparing the denominators, we find that $K_D = EC_{50}^n = EC_{50}^2$. The parameter $EC_{50}$ represents the concentration of ligand that produces half of the maximum effect. This is confirmed by substituting $[L] = EC_{50}$ into our derived equation:\n$$\nE(EC_{50}) = E_{\\max} \\frac{EC_{50}^2}{K_D + EC_{50}^2} = E_{\\max} \\frac{EC_{50}^2}{EC_{50}^2 + EC_{50}^2} = \\frac{1}{2} E_{\\max}\n$$\nThus, the derived minimal function is the Hill equation with a theoretical Hill coefficient of $n=2$.\n\n**Part 2: Parameter Fitting from Experimental Data**\n\nThe task is to fit the parameters $E_{\\max}$, $EC_{50}$, and $n$ of the general Hill model to the provided dose-response data. An analysis consistent with the model involves estimating these parameters from key features of the data.\n\n1.  **Estimation of $E_{\\max}$**: The maximum effect, $E_{\\max}$, is the asymptotic value of the effect $E$ as the ligand concentration $[L]$ becomes very large. Observing the data at high concentrations:\n    - For $[L] = 300 \\ \\mathrm{nM}$, $E = 11.9878 \\ \\text{a.u.}$\n    - For $[L] = 10000 \\ \\mathrm{nM}$, $E = 12.0000 \\ \\text{a.u.}$\n    The response is clearly saturating at a value of $12.0000$. Therefore, we can confidently estimate $E_{\\max} = 12.0 \\ \\text{a.u.}$\n\n2.  **Estimation of $EC_{50}$**: The half-maximal effective concentration, $EC_{50}$, is the ligand concentration at which the effect is half of the maximum. Using our estimate for $E_{\\max}$:\n    $$\n    E = \\frac{E_{\\max}}{2} = \\frac{12.0}{2} = 6.0 \\ \\text{a.u.}\n    $$\n    The provided data includes the point $([L], E) = (10 \\ \\mathrm{nM}, 6.00000 \\ \\text{a.u.})$. This directly and unambiguously identifies the half-maximal concentration. Thus, we estimate $EC_{50} = 10 \\ \\mathrm{nM}$.\n\n3.  **Estimation of the Hill Coefficient $n$**: With robust estimates for $E_{\\max}$ and $EC_{50}$, we can determine $n$ by rearranging the Hill equation and using other data points. The Hill equation can be linearized into a Hill plot form:\n    $$\n    \\log \\left( \\frac{E}{E_{\\max} - E} \\right) = n \\log([L]) - n \\log(EC_{50})\n    $$\n    Let's test this relationship with a data point from the rising part of the curve, for example, $[L] = 3 \\ \\mathrm{nM}$ where $E = 0.990826 \\ \\text{a.u.}$.\n    $$\n    \\frac{E}{E_{\\max} - E} = \\frac{0.990826}{12.0 - 0.990826} = \\frac{0.990826}{11.009174} \\approx 0.0900\n    $$\n    According to the model, this should equal $(\\frac{[L]}{EC_{50}})^n$:\n    $$\n    \\left( \\frac{3}{10} \\right)^n = (0.3)^n\n    $$\n    Setting the two expressions equal: $(0.3)^n = 0.09$. Since $0.3^2 = 0.09$, we find that $n=2$.\n\n    Let's verify with a point on the upper part of the curve, for example, $[L] = 30 \\ \\mathrm{nM}$ where $E=10.8 \\ \\text{a.u.}$:\n    $$\n    \\frac{E}{E_{\\max} - E} = \\frac{10.8}{12.0 - 10.8} = \\frac{10.8}{1.2} = 9.0\n    $$\n    This should equal $(\\frac{[L]}{EC_{50}})^n$:\n    $$\n    \\left( \\frac{30}{10} \\right)^n = 3^n\n    $$\n    Setting them equal: $3^n = 9$. Since $3^2=9$, we again find $n=2$.\n\nThe analysis demonstrates that the experimental data are exceptionally well-described by the Hill equation with parameters $E_{\\max} = 12.0 \\ \\text{a.u.}$, $EC_{50} = 10 \\ \\mathrm{nM}$, and $n=2$. This empirical value for the Hill coefficient is in perfect agreement with the theoretical value derived from the minimal model of dimeric activation. The minor deviations in the data table for some points are considered negligible rounding artifacts or experimental noise.\n\nThe problem asks for the final estimate of $EC_{50}$ in $\\mathrm{nM}$, rounded to three significant figures. Our analysis yields $EC_{50} = 10 \\ \\mathrm{nM}$. To express this with three significant figures, we write $10.0$.", "answer": "$$\\boxed{10.0}$$", "id": "4590975"}, {"introduction": "Understanding a drug's effect requires moving beyond the receptor to model the entire downstream pathway. This practice problem [@problem_id:4590925] challenges you to build a quantitative model that connects the activation of the Liver X Receptor (LXR) to a key physiological outcome: hepatic triglyceride levels. You will integrate receptor occupancy theory with principles of transcriptional regulation and steady-state mass balance to predict how an LXR agonist alters lipid metabolism, a crucial skill in predicting both efficacy and side effects.", "problem": "A clinical pharmacology team is evaluating a liver-targeted agonist of the Liver X receptor (LXR), a ligand-activated transcription factor that forms a heterodimer with the Retinoid X receptor (RXR) and regulates genes involved in lipid metabolism. One principal downstream effector is Sterol Regulatory Element-Binding Protein 1c (SREBP-1c), whose transcriptional induction increases hepatic lipogenesis. Consider a simplified, scientifically grounded model that links LXR activation to steady-state hepatic triglyceride content through the following elements grounded in receptor theory and mass balance:\n\n- Ligand-receptor activation is characterized by fractional receptor activation $f_{R}$ governed by a Hill-type occupancy relation based on mass action, where $f_{R}$ increases with free nuclear ligand concentration $A$ and depends on the dissociation constant $K_{d}$ and the Hill coefficient $n$.\n- The fold-change in SREBP-1c transcription induced by LXR activation is proportional to $f_{R}$ and limited by a maximal transactivation capacity, parameterized by an additional fold above baseline $E_{\\max}$.\n- The fractional change in lipogenesis flux transmitted from SREBP-1c transcription to enzyme activity is scaled by a net efficiency factor $\\eta$ that aggregates translational and post-translational constraints.\n- Hepatic triglyceride content $T$ follows a first-order mass balance with synthesis rate $S$ and clearance rate constant $k_{c}$, so that at steady state the content is determined by the ratio of synthesis to clearance.\n\nYou are provided the following parameter values, which are assumed constant under the experimental conditions:\n\n- Basal triglyceride synthesis rate $S_{0} = 1.8$ mg/g/day.\n- Hepatic triglyceride clearance rate constant $k_{c} = 0.06$ day$^{-1}$.\n- Unbound nuclear LXR agonist concentration $A = 0.50$ $\\mu$M.\n- LXR-ligand dissociation constant $K_{d} = 0.25$ $\\mu$M.\n- Hill coefficient $n = 1$.\n- Maximal additional fold transactivation for SREBP-1c $E_{\\max} = 3.0$ (unitless).\n- Net efficiency of translation of transcriptional induction into lipogenic flux $\\eta = 0.70$ (unitless).\n\nUsing first principles of receptor occupancy, transcriptional regulation, and steady-state mass balance, derive and compute the expected absolute change in steady-state hepatic triglyceride content, defined as $\\Delta T = T_{\\text{ss,agonist}} - T_{\\text{ss,baseline}}$, after LXR activation by the agonist at the given $A$. Express your final answer in mg/g liver and round your answer to four significant figures. Do not use heuristic shortcut formulas; base your derivation on receptor occupancy, transactivation-limited induction, efficiency scaling, and steady-state mass balance.", "solution": "The solution is derived from first principles by modeling the signal cascade from receptor activation to the change in steady-state triglyceride content.\n\n1.  **Steady-State Mass Balance Principle**\n    The hepatic triglyceride content $T$ is governed by a first-order mass balance, expressed by the differential equation:\n    $$\n    \\frac{dT}{dt} = S - k_{c}T\n    $$\n    where $S$ is the synthesis rate and $k_{c}$ is the first-order clearance rate constant. At steady state, the rate of change is zero, $\\frac{dT}{dt} = 0$. This leads to the steady-state content $T_{\\text{ss}}$ being determined by the ratio of synthesis to clearance:\n    $$\n    S - k_{c}T_{\\text{ss}} = 0 \\implies T_{\\text{ss}} = \\frac{S}{k_{c}}\n    $$\n\n2.  **Baseline Steady State**\n    Under basal conditions (no agonist), the synthesis rate is given as $S_{0}$. The baseline steady-state triglyceride content, $T_{\\text{ss,baseline}}$, is therefore:\n    $$\n    T_{\\text{ss,baseline}} = \\frac{S_{0}}{k_{c}}\n    $$\n\n3.  **Agonist-Induced Steady State**\n    In the presence of the LXR agonist, the synthesis rate increases. We must derive the new synthesis rate, $S_{\\text{agonist}}$, by modeling the signal transduction pathway.\n\n    *   **Step 3a: Fractional Receptor Activation ($f_{R}$)**\n        The fractional activation of the LXR receptor by the agonist is described by the Hill equation:\n        $$\n        f_{R} = \\frac{A^{n}}{A^{n} + K_{d}^{n}}\n        $$\n        Given the parameters $A = 0.50$ $\\mu$M, $K_{d} = 0.25$ $\\mu$M, and Hill coefficient $n=1$:\n        $$\n        f_{R} = \\frac{0.50^{1}}{0.50^{1} + 0.25^{1}} = \\frac{0.50}{0.75} = \\frac{2}{3}\n        $$\n\n    *   **Step 3b: Transcriptional Induction and Synthesis Rate ($S_{\\text{agonist}}$)**\n        The problem states that SREBP-1c transcription induction is proportional to $f_R$. The parameter $E_{\\max}$ represents the maximal *additional* fold increase above baseline. The *increase* in the transcriptional signal above baseline is $E_{\\max} \\cdot f_{R}$. This change in transcription is translated into a change in lipogenic flux (synthesis rate) with an efficiency $\\eta$. The fractional increase in the synthesis rate, $\\frac{S_{\\text{agonist}} - S_{0}}{S_{0}}$, is given by the increase in the transcriptional signal scaled by this efficiency:\n        $$\n        \\frac{S_{\\text{agonist}} - S_{0}}{S_{0}} = \\eta \\cdot (E_{\\max} \\cdot f_{R})\n        $$\n        Rearranging this equation gives the new synthesis rate, $S_{\\text{agonist}}$:\n        $$\n        S_{\\text{agonist}} = S_{0} (1 + \\eta E_{\\max} f_{R})\n        $$\n\n    *   **Step 3c: New Steady-State Content ($T_{\\text{ss,agonist}}$)**\n        Using the general steady-state principle, the new steady-state triglyceride content in the presence of the agonist is:\n        $$\n        T_{\\text{ss,agonist}} = \\frac{S_{\\text{agonist}}}{k_{c}} = \\frac{S_{0} (1 + \\eta E_{\\max} f_{R})}{k_{c}}\n        $$\n\n4.  **Calculation of the Absolute Change ($\\Delta T$)**\n    The primary objective is to find the absolute change in steady-state triglyceride content, $\\Delta T = T_{\\text{ss,agonist}} - T_{\\text{ss,baseline}}$.\n    $$\n    \\Delta T = \\frac{S_{0} (1 + \\eta E_{\\max} f_{R})}{k_{c}} - \\frac{S_{0}}{k_{c}}\n    $$\n    Factoring out the $\\frac{S_{0}}{k_{c}}$ term:\n    $$\n    \\Delta T = \\frac{S_{0}}{k_{c}} \\left[ (1 + \\eta E_{\\max} f_{R}) - 1 \\right]\n    $$\n    This simplifies to the final analytical expression for $\\Delta T$:\n    $$\n    \\Delta T = \\frac{S_{0} \\eta E_{\\max} f_{R}}{k_{c}}\n    $$\n\n5.  **Numerical Computation**\n    We now substitute the given numerical values into the derived expression.\n    -   $S_{0} = 1.8$ mg/g/day\n    -   $k_{c} = 0.06$ day$^{-1}$\n    -   $\\eta = 0.70$\n    -   $E_{\\max} = 3.0$\n    -   $f_{R} = \\frac{2}{3}$\n\n    $$\n    \\Delta T = \\frac{(1.8 \\, \\text{mg/g/day}) \\times (0.70) \\times (3.0)}{(0.06 \\, \\text{day}^{-1})} \\times \\left(\\frac{2}{3}\\right)\n    $$\n    Let us compute the value step-by-step:\n    $$\n    \\Delta T = \\frac{1.8 \\times 0.70 \\times 3.0}{0.06} \\times \\frac{2}{3} \\, \\text{mg/g}\n    $$\n    $$\n    \\Delta T = \\frac{3.78}{0.06} \\times \\frac{2}{3} \\, \\text{mg/g}\n    $$\n    $$\n    \\Delta T = 63 \\times \\frac{2}{3} \\, \\text{mg/g}\n    $$\n    $$\n    \\Delta T = 21 \\times 2 \\, \\text{mg/g}\n    $$\n    $$\n    \\Delta T = 42 \\, \\text{mg/g}\n    $$\n    The problem requires the answer to be rounded to four significant figures. Therefore, the result is $42.00$ mg/g.", "answer": "$$\\boxed{42.00}$$", "id": "4590925"}, {"introduction": "Cellular signaling pathways do not operate in isolation; they form complex, interconnected networks. This advanced exercise [@problem_id:4590953] explores the critical concept of signal crosstalk through resource competition, where multiple nuclear receptors must vie for a limited pool of the essential heterodimerization partner, RXR. By applying equilibrium binding principles to this competitive system, you will learn to predict how changes in a shared cellular resource can redistribute signaling activity and alter the balance between distinct metabolic pathways.", "problem": "In a hepatocyte nucleus, three nuclear receptors—Peroxisome Proliferator-Activated Receptor alpha (PPAR$\\alpha$), Liver X Receptor beta (LXR$\\beta$), and Farnesoid X Receptor (FXR)—each require heterodimerization with Retinoid X Receptor (RXR) to bind DNA and activate their target genes. Assume a single shared pool of RXR and that all three receptors compete for RXR at a single binding site per RXR molecule. The following quantities are measured under basal conditions: total RXR concentration $R_{T} = 15\\,\\mathrm{nM}$; total partner concentrations $P_{T} = 50\\,\\mathrm{nM}$ for PPAR$\\alpha$, $L_{T} = 20\\,\\mathrm{nM}$ for LXR$\\beta$, and $F_{T} = 10\\,\\mathrm{nM}$ for FXR; heterodimerization dissociation constants $K_{d,P} = 10\\,\\mathrm{nM}$, $K_{d,L} = 2\\,\\mathrm{nM}$, and $K_{d,F} = 0.5\\,\\mathrm{nM}$. Ligand occupancy fractions for each partner are given by $\\theta_{i} = \\frac{L_{i}}{L_{i} + K_{L,i}}$, with ligand concentrations and apparent dissociation constants $L_{P} = 80\\,\\mathrm{nM}$, $K_{L,P} = 20\\,\\mathrm{nM}$; $L_{L} = 15\\,\\mathrm{nM}$, $K_{L,L} = 10\\,\\mathrm{nM}$; and $L_{F} = 10\\,\\mathrm{nM}$, $K_{L,F} = 10\\,\\mathrm{nM}$. Coactivator-mediated transactivation efficacy constants are $\\kappa_{P} = 1.0$, $\\kappa_{L} = 1.1$, and $\\kappa_{F} = 0.9$ (each in units that render the final activation a dimensionless relative activation unit when multiplied by a concentration in $\\mathrm{nM}$ and $\\theta_{i}$).\n\nAssume: (i) heterodimerization follows the law of mass action; (ii) PPAR$\\alpha$, LXR$\\beta$, and FXR are present in large excess relative to RXR so that their free concentrations remain approximately equal to their totals; (iii) homodimerization and other complexes are negligible; and (iv) the instantaneous target gene activation level $A_{i}$ for pathway $i \\in \\{P,L,F\\}$ is proportional to the concentration of the corresponding liganded heterodimer, $A_{i} = \\kappa_{i}\\,\\theta_{i}\\,[C_{i}]$, where $[C_{i}]$ is the concentration of the RXR–partner heterodimer.\n\nStarting from these assumptions and fundamental mass-action binding principles, derive the expression for the distribution of the limited RXR pool among the three heterodimers and compute the new target gene activation levels for PPAR$\\alpha$, LXR$\\beta$, and FXR when RXR expression is reduced by half (i.e., $R_{T}$ decreases from $15\\,\\mathrm{nM}$ to $7.5\\,\\mathrm{nM}$). Express your final numerical values for $(A_{P}, A_{L}, A_{F})$ in a single row matrix using relative activation units (dimensionless) and round your answer to four significant figures.", "solution": "The solution involves modeling a competitive binding equilibrium for the limited pool of RXR and then calculating the resulting activation levels for each pathway.\n\nThe system consists of a single shared pool of RXR available to bind competitively to three different partner receptors: PPAR$\\alpha$ (P), LXR$\\beta$ (L), and FXR (F). The equilibrium reactions for heterodimer formation are:\n$R + P \\rightleftharpoons C_P$\n$R + L \\rightleftharpoons C_L$\n$R + F \\rightleftharpoons C_F$\nwhere $[R]$, $[P]$, $[L]$, $[F]$ are the concentrations of the free monomers, and $[C_P]$, $[C_L]$, $[C_F]$ are the concentrations of the RXR-PPAR$\\alpha$, RXR-LXR$\\beta$, and RXR-FXR heterodimers, respectively.\n\nBased on the law of mass action (Assumption i), the dissociation constants are defined as:\n$$K_{d,P} = \\frac{[R][P]}{[C_P]}, \\quad K_{d,L} = \\frac{[R][L]}{[C_L]}, \\quad K_{d,F} = \\frac{[R][F]}{[C_F]}$$\nWe can rearrange these expressions to solve for the heterodimer concentrations:\n$$[C_P] = \\frac{[R][P]}{K_{d,P}}, \\quad [C_L] = \\frac{[R][L]}{K_{d,L}}, \\quad [C_F] = \\frac{[R][F]}{K_{d,F}}$$\nUsing Assumption (ii), that the partner receptors are in large excess, we approximate their free concentrations with their total concentrations: $[P] \\approx P_T$, $[L] \\approx L_T$, and $[F] \\approx F_T$. The expressions become:\n$$[C_P] = \\frac{[R] P_T}{K_{d,P}}, \\quad [C_L] = \\frac{[R] L_T}{K_{d,L}}, \\quad [C_F] = \\frac{[R] F_T}{K_{d,F}}$$\nThe total concentration of RXR, $R_T$, is conserved and is the sum of free RXR and all bound forms of RXR (Assumption iii allows us to neglect other complexes):\n$$R_T = [R] + [C_P] + [C_L] + [C_F]$$\nSubstituting the expressions for the heterodimer concentrations into the conservation equation for RXR:\n$$R_T = [R] + \\frac{[R] P_T}{K_{d,P}} + \\frac{[R] L_T}{K_{d,L}} + \\frac{[R] F_T}{K_{d,F}}$$\nFactoring out the free RXR concentration, $[R]$:\n$$R_T = [R] \\left( 1 + \\frac{P_T}{K_{d,P}} + \\frac{L_T}{K_{d,L}} + \\frac{F_T}{K_{d,F}} \\right)$$\nSolving for $[R]$:\n$$[R] = \\frac{R_T}{1 + \\frac{P_T}{K_{d,P}} + \\frac{L_T}{K_{d,L}} + \\frac{F_T}{K_{d,F}}}$$\nThis expression allows us to calculate the free RXR concentration from the given total concentrations and dissociation constants. We are asked to compute the new activation levels when $R_T$ is reduced to $R_T' = 7.5\\,\\mathrm{nM}$.\n\nFirst, we calculate the dimensionless constant terms.\nThe ligand occupancy fractions, $\\theta_i$, are:\n$$\\theta_P = \\frac{L_P}{L_P + K_{L,P}} = \\frac{80}{80 + 20} = \\frac{80}{100} = 0.8$$\n$$\\theta_L = \\frac{L_L}{L_L + K_{L,L}} = \\frac{15}{15 + 10} = \\frac{15}{25} = 0.6$$\n$$\\theta_F = \\frac{L_F}{L_F + K_{L,F}} = \\frac{10}{10 + 10} = \\frac{10}{20} = 0.5$$\n\nNext, we compute the terms in the denominator of the expression for $[R]$. These ratios represent the binding strengths of the partners scaled by their concentrations.\n$$\\frac{P_T}{K_{d,P}} = \\frac{50\\,\\mathrm{nM}}{10\\,\\mathrm{nM}} = 5$$\n$$\\frac{L_T}{K_{d,L}} = \\frac{20\\,\\mathrm{nM}}{2\\,\\mathrm{nM}} = 10$$\n$$\\frac{F_T}{K_{d,F}} = \\frac{10\\,\\mathrm{nM}}{0.5\\,\\mathrm{nM}} = 20$$\nThe denominator term is:\n$$D = 1 + \\frac{P_T}{K_{d,P}} + \\frac{L_T}{K_{d,L}} + \\frac{F_T}{K_{d,F}} = 1 + 5 + 10 + 20 = 36$$\nNow we calculate the new heterodimer concentrations, denoted $[C_i]'$, using the new total RXR concentration $R_T' = 7.5\\,\\mathrm{nM}$.\nFirst, the new free RXR concentration, $[R]'$:\n$$[R]' = \\frac{R_T'}{D} = \\frac{7.5}{36}\\,\\mathrm{nM} = \\frac{5}{24}\\,\\mathrm{nM}$$\nThe new heterodimer concentrations are:\n$$[C_P]' = [R]' \\left( \\frac{P_T}{K_{d,P}} \\right) = \\left( \\frac{7.5}{36} \\right) (5) = \\frac{37.5}{36}\\,\\mathrm{nM} = \\frac{25}{24}\\,\\mathrm{nM}$$\n$$[C_L]' = [R]' \\left( \\frac{L_T}{K_{d,L}} \\right) = \\left( \\frac{7.5}{36} \\right) (10) = \\frac{75}{36}\\,\\mathrm{nM} = \\frac{25}{12}\\,\\mathrm{nM}$$\n$$[C_F]' = [R]' \\left( \\frac{F_T}{K_{d,F}} \\right) = \\left( \\frac{7.5}{36} \\right) (20) = \\frac{150}{36}\\,\\mathrm{nM} = \\frac{25}{6}\\,\\mathrm{nM}$$\nFinally, we compute the new target gene activation levels, $A_i'$, using the formula $A_i' = \\kappa_i \\theta_i [C_i]'$:\n$$A_P' = \\kappa_P \\theta_P [C_P]' = (1.0)(0.8)\\left(\\frac{25}{24}\\right) = \\frac{4}{5} \\times \\frac{25}{24} = \\frac{100}{120} = \\frac{5}{6}$$\n$$A_L' = \\kappa_L \\theta_L [C_L]' = (1.1)(0.6)\\left(\\frac{25}{12}\\right) = 0.66 \\times \\frac{25}{12} = \\frac{16.5}{12} = \\frac{33}{24} = \\frac{11}{8}$$\n$$A_F' = \\kappa_F \\theta_F [C_F]' = (0.9)(0.5)\\left(\\frac{25}{6}\\right) = 0.45 \\times \\frac{25}{6} = \\frac{11.25}{6} = \\frac{45}{24} = \\frac{15}{8}$$\nThe problem requires numerical values rounded to four significant figures.\n$$A_P' = \\frac{5}{6} \\approx 0.833333... \\rightarrow 0.8333$$\n$$A_L' = \\frac{11}{8} = 1.375 \\rightarrow 1.375$$\n$$A_F' = \\frac{15}{8} = 1.875 \\rightarrow 1.875$$\nThese values represent the new relative activation units for the PPAR$\\alpha$, LXR$\\beta$, and FXR pathways, respectively.", "answer": "$$\\boxed{\\begin{pmatrix} 0.8333  1.375  1.875 \\end{pmatrix}}$$", "id": "4590953"}]}